The same system that regulates your blood pressure may be holding open the door for cancer metastasis.
We often think of cancer as a single disease, but the real danger often lies in its ability to spread—a process known as metastasis. For melanoma, the deadliest form of skin cancer, this frequently means traveling through the blood to form new tumors in the lungs.
Surprisingly, a key player in this process isn't a rare cancer gene, but a common peptide in your body: angiotensin II, a well-known regulator of blood pressure. Recent research has uncovered its dark side, revealing how this ordinary molecule can create a "welcome mat" for circulating cancer cells in our blood vessels, paving the way for metastatic disease.
To understand how this happens, we need to look at the renin-angiotensin system (RAS). This complex system plays a critical role in regulating blood pressure and fluid balance in our bodies. When it's activated, it can lead to hypertension.
At the heart of this system is angiotensin II, a potent peptide that raises blood pressure. While this is a normal physiological function, the problem begins when this system goes into overdrive. High levels of angiotensin II are particularly frequent in malignant hypertension and renal hypertension, observed in about 90% of patients with these conditions 6 .
For years, scientists have noticed troubling connections between hypertension and cancer progression through epidemiological studies. Cancer patients often have hypertension as a comorbidity, and many chemotherapy drugs can themselves cause high blood pressure 1 6 . This suggested a deeper biological link was at play.
High levels of angiotensin II create a pro-adhesive environment in blood vessels, making it easier for circulating cancer cells to stick and form new tumors.
of patients with malignant hypertension have high angiotensin II levels
Metastasis is a multi-step process that cancer cells must complete to form new tumors in distant organs. For hematogenous metastasis (spread through the bloodstream), the journey is particularly perilous.
Cancer cells break away from the original tumor mass.
Cells invade blood vessels to enter circulation.
Cells must withstand immune attacks and physical stress in the bloodstream.
The sticking point—literally—is this step. To exit the bloodstream, circulating tumor cells must first adhere to the vascular endothelial cells that line the interior of blood vessels 6 . This adhesion is the critical gateway that determines whether a cancer cell can leave the blood and invade a new organ.
Cells proliferate and form a new tumor at the distant site.
Under normal circumstances, endothelial cells form a tight, continuous monolayer that acts as a protective barrier 2 . But in the presence of certain signals, these cells can become activated, expressing adhesion molecules that act like Velcro for passing cancer cells.
To investigate the angiotensin II connection, a team of researchers designed a crucial experiment using a mouse model of hematogenous metastasis 1 6 . Their methodology was systematic:
They intravenously injected B16/F10 mouse melanoma cells into C57BL/6 mice, simulating the stage when cancer cells are circulating in the bloodstream and looking for a place to land.
They administered angiotensin II to these mice at different doses (0.5, 1, and 2 μg/kg/min) continuously for two weeks, while a control group received only a vehicle solution.
To confirm that any effect was specifically through angiotensin II signaling, they tested two types of blood pressure medications: valsartan (an angiotensin receptor blocker) and amlodipine (a calcium channel blocker).
They used genetically engineered mice that lacked the angiotensin II receptor (Agtr1a) specifically in their vascular endothelial cells.
They examined the expression of adhesion molecules in lung vascular endothelial cells and used an anti-E-selectin antibody to block this specific molecule.
The results were striking. Angiotensin II dramatically increased lung metastasis in a dose-dependent manner:
| Treatment Group | Dose of Angiotensin II | Metastatic Colonies |
|---|---|---|
| Control | Vehicle only | Baseline (low) |
| Experimental Group 1 | 0.5 μg/kg/min | Moderate increase |
| Experimental Group 2 | 1 μg/kg/min | Significant increase |
| Experimental Group 3 | 2 μg/kg/min | Highest number |
| Treatment Approach | Effect on Metastasis |
|---|---|
| Angiotensin II alone | Significant increase |
| Angiotensin II + Valsartan (ARB) | Blocked |
| Angiotensin II + Amlodipine (CCB) | No blocking |
| Endothelial-specific Agtr1a KO mice | Significantly diminished |
The most crucial finding came when they looked at the molecular mechanism. They discovered that angiotensin II treatment significantly increased E-selectin mRNA expression in vascular endothelial cells collected from lung tissues 1 .
When they used an anti-E-selectin antibody to block this molecule, the angiotensin II-accelerated lung metastases were significantly suppressed 1 . E-selectin is a specific adhesion molecule that acts like a grappling hook, catching circulating cells.
| Molecule | Role in Process | Effect of Blocking |
|---|---|---|
| Angiotensin II | Primary signaling molecule | N/A |
| AT1R (Agtr1a) | Receptor on vascular endothelial cells | Diminishes metastasis |
| E-selectin | Adhesion molecule that captures cancer cells | Suppresses metastasis |
Angiotensin II increases E-selectin expression on vascular endothelial cells, creating "molecular Velcro" that captures circulating cancer cells and facilitates their exit from blood vessels to form metastases.
The discovery of this pathway was made possible by specific research tools. Here are some of the key reagents used in this field and their functions:
Standardized cancer cell line for metastasis studies
Selective angiotensin II receptor blocker (ARB)
Blocks specific adhesion molecule function
Allows endothelial-specific gene deletion
Provides continuous, controlled delivery of the peptide
This research provides a powerful explanation for the long-observed link between hypertension and cancer progression. It suggests that high angiotensin II levels create a pro-adhesive environment inside blood vessels, making it easier for any circulating cancer cells to stick and form new tumors.
The findings also shed light on why some epidemiological studies have found that patients taking angiotensin receptor blockers (ARBs) might have better cancer outcomes 6 . These drugs may be doing more than just controlling blood pressure—they might be indirectly slamming the door on metastasis.
This doesn't mean that blood pressure medications are cancer treatments, but it does open exciting new avenues for research.
The discovery that a common blood pressure regulator can fuel cancer's spread is a perfect example of how interconnected our bodily systems are. The same molecule that helps maintain our blood pressure can, under the right circumstances, become an accomplice to cancer metastasis.
As research continues, scientists are exploring how to leverage this knowledge into better treatments. The goal isn't just to kill cancer cells, but to make the body's environment less hospitable to their spread—creating biological "no vacancy" signs that tell circulating cancer cells to move along.
What makes this research particularly compelling is that it reminds us that sometimes the most powerful insights come from connecting seemingly unrelated processes—bridging the worlds of cardiovascular biology and oncology to uncover new pathways toward defeating cancer.
References will be added here in the proper format.